Skip to main
VKTX
VKTX logo

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics Inc. is positioned for positive growth due to its strategic focus on enhancing clinical updates and expanding strategic options for its pipeline, which includes promising compounds like VK2809, VK5211, and VK0214. The company's emphasis on orally available formulations, particularly VK2735, is expected to enhance patient compliance and treatment convenience, making it a strong contender in the obesity treatment market. Additionally, the anticipated differentiation of its products, along with potential monthly dosing regimens, is likely to attract favorable financing and partnering opportunities, underpinning a solid outlook for the company's future performance.

Bears say

Viking Therapeutics faces significant risks that could hinder its progress, primarily stemming from the potential for failed or inconclusive clinical trials and the challenge of securing sufficient funding for its drug development pipeline. The company operates in a volatile industry, characterized by regulatory uncertainty and unpredictable clinical outcomes, which could adversely impact its product candidates. Additionally, the increasing complexity and price sensitivity of commercial markets further complicate the landscape for Viking Therapeutics, potentially jeopardizing its financial performance and outlook.

Viking Therapeutics (VKTX) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 12 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.